Related Experiment Video
Updated: Sep 25, 2025

Identifying Microglia and Peripheral Infiltrating Macrophages in the Injured Spinal Cords Using Flow Cytometry
Published on: June 24, 2025
Macrophage-based delivery of interleukin-13 improves functional and histopathological outcomes following spinal cord
Jana Van Broeckhoven1, Céline Erens1, Daniela Sommer1
1Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590, Diepenbeek, Belgium.
Background:
Spinal cord injury (SCI) elicits a robust neuroinflammatory reaction which, in turn, exacerbates the initial mechanical damage. Pivotal players orchestrating this response are macrophages (Mφs) and microglia. After SCI, the inflammatory environment is dominated by pro-inflammatory Mφs/microglia, which contribute to secondary cell death and prevent regeneration. Therefore, reprogramming Mφ/microglia towards a more anti-inflammatory and potentially neuroprotective phenotype has gained substantial therapeutic interest in recent years. Interleukin-13 (IL-13) is a potent inducer of such an anti-inflammatory phenotype. In this study, we used genetically modified Mφs as carriers to continuously secrete IL-13 (IL-13 Mφs) at the lesion site.
Methods:
Mφs were genetically modified to secrete IL-13 (IL-13 Mφs) and were phenotypically characterized using qPCR, western blot, and ELISA. To analyze the therapeutic potential, the IL-13 Mφs were intraspinally injected at the perilesional area after hemisection SCI in female mice. Functional recovery and histopathological improvements were evaluated using the Basso Mouse Scale score and immunohistochemistry. Neuroprotective effects of IL-13 were investigated using different cell viability assays in murine and human neuroblastoma cell lines, human neurospheroids, as well as murine organotypic brain slice cultures.
Results:
In contrast to Mφs prestimulated with recombinant IL-13, perilesional transplantation of IL-13 Mφs promoted functional recovery following SCI in mice. This improvement was accompanied by reduced lesion size and demyelinated area. The local anti-inflammatory shift induced by IL-13 Mφs resulted in reduced neuronal death and fewer contacts between dystrophic axons and Mφs/microglia, suggesting suppression of axonal dieback. Using IL-4Rα-deficient mice, we show that IL-13 signaling is required for these beneficial effects. Whereas direct neuroprotective effects of IL-13 on murine and human neuroblastoma cell lines or human neurospheroid cultures were absent, IL-13 rescued murine organotypic brain slices from cell death, probably by indirectly modulating the Mφ/microglia responses.
Conclusions:
Collectively, our data suggest that the IL-13-induced anti-inflammatory Mφ/microglia phenotype can preserve neuronal tissue and ameliorate axonal dieback, thereby promoting recovery after SCI.
Insights
Genetically engineered macrophages secreting Interleukin-13 (IL-13) promoted functional recovery after spinal cord injury (SCI) in mice. This approach reduced inflammation and neuronal death, preserving tissue and improving outcomes.
Area of Science:
- Neuroscience
- Immunology
- Regenerative Medicine
Background:
- Spinal cord injury (SCI) triggers neuroinflammation, involving macrophages (Mφs) and microglia, which worsens damage and hinders regeneration.
- Pro-inflammatory Mφs/microglia contribute to secondary cell death post-SCI.
- Reprogramming Mφs/microglia to an anti-inflammatory phenotype is a therapeutic target.
Purpose of the Study:
- To investigate the therapeutic potential of genetically modified Mφs engineered to continuously secrete Interleukin-13 (IL-13) at the SCI lesion site.
- To assess if sustained IL-13 delivery via Mφs can promote functional recovery and neuroprotection after SCI.
Main Methods:
- Genetically modified Mφs (IL-13 Mφs) were created to secrete IL-13.
- IL-13 Mφs were intraspinally injected into female mice after hemisection SCI.
- Functional recovery (Basso Mouse Scale) and histopathology (lesion size, demyelination) were evaluated.
- Neuroprotective effects were assessed in vitro using cell lines, neurospheroids, and organotypic brain slices.
Main Results:
- Perilesional transplantation of IL-13 Mφs significantly promoted functional recovery in SCI mice.
- This functional improvement correlated with reduced lesion size, demyelination, and neuronal death.
- IL-13 Mφs suppressed axonal dieback by reducing dystrophic axon-Mφ/microglia contact.
- IL-13 signaling via IL-4Rα was essential for the observed beneficial effects.
Conclusions:
- Sustained IL-13 delivery via engineered Mφs can reprogram the Mφ/microglia phenotype towards an anti-inflammatory state.
- This approach preserves neuronal tissue and reduces axonal dieback, promoting recovery after SCI.
- IL-13 Mφs offer a promising cell-based therapy for spinal cord injury.
More Related Videos
08:43Intravital Imaging of Axonal Interactions with Microglia and Macrophages in a Mouse Dorsal Column Crush Injury
Published on: November 23, 2014
08:52Neuron-Macrophage Co-cultures to Activate Macrophages Secreting Molecular Factors with Neurite Outgrowth Activity
Published on: March 30, 2018